Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Thompson

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
International Journal of Radiation Oncology, Biology, Physics|March 1, 2017
Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder CancerCatherine Thompson, Nuradh Joseph, Benjamin Sanderson, et al.
Plos One|September 3, 2011
Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UKMonica Galiano, Paul-Michael Agapow, Catherine Thompson, et al.
BMC Public Health|August 29, 2009
Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centersJustin Mandala, Kwasi Torpey, Prisca Kasonde, et al.
European Urology|July 30, 2011
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trialFrancisco Cruz, Sender Herschorn, Philip Aliotta, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|October 7, 2022
Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line TreatmentSaid Hilton, Philippe Kestemont, Gerhard Sattler, et al.
European Urology|April 24, 2013
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trialChristopher Chapple, Karl-Dietrich Sievert, Scott MacDiarmid, et al.
Emerging Infectious Diseases|October 25, 2012
Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011Katja Hoschler, Catherine Thompson, Nick Andrews, et al.
The Journal of Urology|October 19, 2010
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trialRoger Dmochowski, Christopher Chapple, Victor W Nitti, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 6, 2021
Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy SubjectsKarl Heinz Weiss, Catherine Thompson, Peter Dogterom, et al.
Clinical Infection in Practice|December 31, 2019
Adenovirus Type 7 causing severe lower respiratory tract infection in immunocompetent adults: a comparison of two contrasting cases from an intensive care unit in North West EnglandTom Wingfield, Luke Dearden, Pete Calvert, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
International Journal of Radiation Oncology, Biology, Physics|March 1, 2017
Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder CancerCatherine Thompson, Nuradh Joseph, Benjamin Sanderson, et al.
Plos One|September 3, 2011
Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UKMonica Galiano, Paul-Michael Agapow, Catherine Thompson, et al.
BMC Public Health|August 29, 2009
Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centersJustin Mandala, Kwasi Torpey, Prisca Kasonde, et al.
European Urology|July 30, 2011
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trialFrancisco Cruz, Sender Herschorn, Philip Aliotta, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|October 7, 2022
Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line TreatmentSaid Hilton, Philippe Kestemont, Gerhard Sattler, et al.
European Urology|April 24, 2013
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trialChristopher Chapple, Karl-Dietrich Sievert, Scott MacDiarmid, et al.
Emerging Infectious Diseases|October 25, 2012
Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011Katja Hoschler, Catherine Thompson, Nick Andrews, et al.
The Journal of Urology|October 19, 2010
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trialRoger Dmochowski, Christopher Chapple, Victor W Nitti, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 6, 2021
Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy SubjectsKarl Heinz Weiss, Catherine Thompson, Peter Dogterom, et al.
Clinical Infection in Practice|December 31, 2019
Adenovirus Type 7 causing severe lower respiratory tract infection in immunocompetent adults: a comparison of two contrasting cases from an intensive care unit in North West EnglandTom Wingfield, Luke Dearden, Pete Calvert, et al.
Pageof 8